Landscape of germline cancer predisposition mutations testing and management in pediatrics: Implications for research and clinical care

Shilpa A. Shahani, Erin L. Marcotte

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

As germline genetic testing capacities have improved over the last two decades, increasingly more people are newly diagnosed with germline cancer susceptibility mutations. In the wake of this growth, there remain limitations in both testing strategies and translation of these results into morbidity- and mortality-reducing practices, with pediatric populations remaining especially vulnerable. To face the challenges evoked by an expanding diversity of germline cancer mutations, we can draw upon a model cancer-associated genetic condition for which we have developed a breadth of expertise in managing, Trisomy 21. We can additionally apply advances in other disciplines, such as oncofertility and pharmacogenomics, to enhance care delivery. Herein, we describe the history of germline mutation testing, epidemiology of known germline cancer mutations and their associations with childhood cancer, testing limitations, and future directions for research and clinical care.

Original languageEnglish (US)
Article number1011873
JournalFrontiers in Pediatrics
Volume10
DOIs
StatePublished - Sep 26 2022

Bibliographical note

Funding Information:
This work was supported by the Children's Cancer Research Fund (Minneapolis, MN).

Publisher Copyright:
Copyright © 2022 Shahani and Marcotte.

Keywords

  • cancer predisposition
  • cancer syndrome
  • childhood cancer
  • genetic testing
  • germline predisposition

Fingerprint

Dive into the research topics of 'Landscape of germline cancer predisposition mutations testing and management in pediatrics: Implications for research and clinical care'. Together they form a unique fingerprint.

Cite this